Debussy International Limited investment portfolio

CellVoyant Technologies Ltd offers AI‑driven platforms for cell‑based therapeutic development, including FateView—a cloud‑based predictive cell analytics tool that uses label‑free microscopy and machine‑learning to forecast cell states—and FateDrive, an AI‑guided optimisation service that models and simulates process conditions to improve yield, quality and reproducibility for biotechnology and pharmaceutical companies.

Chemify Limited operates a digital chemistry platform that uses AI‑driven “chemputation” and robotic automation to design, synthesize and scale complex molecules. Its services target chemical manufacturers, pharmaceutical developers and research organisations seeking rapid, data‑rich molecular discovery.